The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index; 88 of the 108 sources its claims cite were checked for support.
Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer
Open accessAbstract
Gastric cancer (GC) is one of the most common cancers worldwide. Most patients are diagnosed at the progressive stage of the disease, and current anticancer drug advancements are still lacking. Therefore, it is crucial to find relevant biomarkers with the accurate prediction of prognoses and good predictive accuracy to select appropriate patients with GC. Recent advances in molecular profiling technologies, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, have enabled the approach of GC biology at multiple levels of omics interaction networks. Systemic biological analyses, such as computational inference of "big data" and advanced bioinformatic approaches, are emerging to identify the key molecular biomarkers of GC, which would benefit targeted therapies. This review summarizes the current status of how bioinformatics analysis contributes to biomarker discovery for prognosis and prediction of therapeutic efficacy in GC based on a search of the medical literature. We highlight emerging individual multi-omics datasets, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics, for validating putative markers. Finally, we discuss the current challenges and future perspectives to integrate multi-omics analysis for improving biomarker implementation. The practical integration of bioinformatics analysis and multi-omics datasets under complementary computational analysis is having a great impact on the search for predictive and prognostic biomarkers and may lead to an important revolution in treatment.
Overview
CoChat Summary
TL;DR
This narrative review summarizes how bioinformatics and single- or multi-omics analyses have been used to identify predictive and prognostic biomarkers in gastric cancer across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and pharmacogenomics. It argues that integrating multi-omics with computational and machine-learning methods may improve patient stratification and therapy selection, but clinical translation still requires validation, standardization, and large trials.
Key findings
- Across omics layers, many candidate signatures are reported: a six-metastasis-related gene set; 50 DEGs from 375 TCGA GC samples with 10 linked to outcome and macrophage infiltration; 39 prognostic gene signatures with COL1A1, COL1A2, and EGFR each identified three times; an 11-DMS methylation signature; an eight-MDEG signature; 110 differentially expressed miRNAs with a three-miRNA prognostic signature; 18 immune-related lncRNAs; 429 differentially expressed proteins; 24 survival-associated metabolites with 8 independent prognostic metabolites; and a 28-metabolite model with AUROC 0.832 and concordance index 0.83, in which 11 metabolites significantly discriminated prognosis.
- Pharmacogenomic and therapeutic prediction studies identified a three-gene platinum-response model (ND6, BRMS1, SRXN1) from 23 survival-related genes; in silico TCGA analysis predicted up to 15% of GC samples would benefit from currently approved targeted therapy versus 50% from FDA-approved alternative targeted therapies; proteomic subtypes from 206 pretreatment tumor samples were linked to XELOX, DOS, and anti-HER2 therapy; and four serum metabolites distinguished chemo-sensitive from chemo-resistant tumors with 82.5% sensitivity and specificity.
- Multi-omics integration remains challenging: TCGA and ACRG molecular classifications exist but clinical use is limited by intricacy, and no alternative marker set has yet outperformed them; a deep-learning autoencoder using RNA-seq, miRNA-seq, and DNA methylation identified two prognostic subgroups and outperformed PCA and similarity network fusion. Three bioinformatics-based GC clinical trials are ongoing (NCT06035250, NCT05319392, NCT05985577) and one is completed (NCT05620537).
- Microbiome analysis of 128 samples detected 5,450 phylotypes belonging to 19 phyla and 296 genera; enrichment of *Fusobacterium nucleatum* and *Prevotella* I in cancerous tissues was associated with worse survival.
Methods
- Non-systematic review based on electronic searches of PubMed and Google Scholar using keywords including “gastric cancer”, “bioinformatics analysis”, “multi-omics”, “artificial intelligence”, “machine learning”, “prognosis”, “prediction”, and “biomarker”.
- Included review articles and guidelines from 2018 to 2023 on bioinformatic approaches to GC genetic, epigenetic, transcriptomic, proteomic, and metabolic processes; only full English articles published within the last ten years were considered. Exclusions were duplicate articles, studies lacking diagnostic outcomes, case reports, correspondence, letters, and non-human research.
- No primary data collection, systematic quality appraisal, or meta-analysis was performed; the paper summarizes cited studies and tabulated biomarker examples.
Limitations
- The paper states that this is a non-systematic review and lists obstacles to clinical implementation: need for large phenotypically characterized datasets, high accuracy and reproducibility, difficulty obtaining suitable tissue samples, strict sample preparation requirements, high costs, incompatible data across databases, need to normalize patient characteristics such as age, race, and stage, and validation through comprehensive cohort studies and large-scale clinical trials; data standardization and benchmarking of integration methods are also needed.
- Evident from the text and tables: many cited biomarker studies rely on public databases and/or small cohorts (e.g., n=18, 31, 37, 48, 65 in some tables), with limited external validation, and no systematic quality appraisal or quantitative synthesis is reported.
- Evident: as a narrative review, it does not provide new experimental validation and cannot establish the clinical utility of the listed candidate markers.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
81 Valid · 4 Not valid · 12 Not checked · 12 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Ten of the fifty genes (RXRG, AGT, BCHE, UBE2QL1, PLCXD3, ADCYAP1R1, NRCAM, MAMDC2, CDH19, and GAMT) were linked with the outcome and macrophage infiltration in GC.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Supportedcites [14] Gao, 2022, Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer, Front. Oncol. source
The Results (Survival Analysis) identify these exact ten genes among fifty as having prognostic significance in gastric cancer. The Results (Relationship Between Gene Expression and Immune Cell Infiltration) report that the ten genes’ expression was most closely related to macrophages, with correlations of varying strength. (LLM, conf=0.91)
plainstates an associationn = 375- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Based on 375 TCGA GC samples, 50 DEGs between GC and paired normal tissues were identified [14].”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Partly supportedcites [14] Gao, 2022, Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer, Front. Oncol. sourceExperimental — accuracy not yet measured
The Data Collection section reports 375 TCGA primary cancers and 32 non-tumor tissues, and the Results report a comparison between gastric cancer and normal tissues. But Screening of Differentially Expressed Genes reports 3,213 differential genes; Intersecting Genes identifies 50 genes at the intersection with a trend-analysis module. The copy does not describe the normal tissues as paired with the cancers. No page numbers are available in our copy. (LLM, conf=0.90)
plainstates an associationn = 375- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, metabolic patterns changed before- and after surgical procedures in GC.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Supportedcites [63] Song, 2023, Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers, Metabolomics source
The Results section, “Metabolic differences before and after surgery,” explicitly states that metabolic patterns differed before and after surgery, particularly in gastric cancer (GC) subjects. It reports a comparison of plasma metabolomics from the same subjects at both time points. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Besides, highly expressed extracellular matrix proteins (THSD4, SRPX2, TGFBI, THBS1, and LAMB2) can serve as indicators to predict drug resistance.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 7. Pharmacogenomics-Based Validation of Predictive Markers of GC
What the sources say
- Supportedcites [72] Li, 2022, Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies, Nat. Commun. source
The Results section, “Proteomic subtyping of the GC cohort and their association with a therapeutic response” (page not provided), names all five proteins and reports higher expression in a chemotherapy non-sensitive group. It concludes that these extracellular matrix proteins are associated with drug resistance and could indicate chemotherapy response. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A major GC target identified in this analysis was the high frequency of PIK3CA mutation variants.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 7. Pharmacogenomics-Based Validation of Predictive Markers of GC
What the sources say
- Supportedcites [70] Hescheler, 2020, Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data, Gastric Cancer source
The Discussion describes a major gastric-cancer target identified by the analysis as the high incidence of PIK3CA mutation variants. The Results section on mutation variants identifies the relevant mutation hotspots. The citing sentence is a close paraphrase. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 41 with their cited sources checked
Create a free account to see all 109 claims and to verify the 2 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 38
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
“Among the six common hub genes, TRYOBP and C1QB were negatively associated with the overall survival (OS) of the GC patients.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > References
“Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
“Seventeen differential metabolites (sulfite, TG (54:2), TG (53:4), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methyl alanine, 3-hydroxysteroid, CL (63:4), PE-NMe (40:5), retinol, MG (21:0/0:0/0:0), tetradecanoic acid, tridecanoic acid, octacosanoic acid and myristate glycine)”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
“sulfite, TG (54:2), TG (53:4), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methyl alanine, 3-hydroxysteroid, CL (63:4), PE-NMe (40:5), retinol, MG (21:0/0:0/0:0), tetradecanoic acid, tridecanoic acid, octacosanoic acid and myristate glycine”
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Gastric cancer (GC) is a common cancer type, with more than one million new cases each year [1].”
BackgroundWGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174 · cited 1×
“Transcriptomes denote all RNA molecules created in a cell from the genome under certain pathological situations [29,30].”
BackgroundSTRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 1×
“…interaction (PPI) networks and weighted gene co-expression network analysis (WGCNA) based on the RNA sequencing and microarray data have been revealed to establish potent organized biological strategies for mining the functional gene modules and detecting novel prognostic biomarkers [11,12].”
MethodBang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · cited 1×
“Despite these advances in knowledge only one oncogenic driver-based therapy (Her2-directed treatment with trastuzumab) has shown acceptable survival benefit [5].”
BackgroundComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · cited 1×
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
BackgroundNomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292 · cited 1×
“The nomogram has been broadly utilized as a predictive method in oncology for a decade [23].”
MethodMolecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223 · cited 1×
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
BackgroundSimilarity network fusion for aggregating data types on a genomic scale
Wang, B., Mezlini, A. M., Demir, F., Fiume, M., Tu, Z., Brudno, M., Haibe-Kains, B., & Goldenberg, A. (2014) · Nature Methods · doi:10.1038/nmeth.2810 · Cited by 2,036 · cited 1×
“…[97], iClusterPlus [98], Patient-specific data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein…”
BackgroundThe NIH Roadmap Epigenomics Mapping Consortium
Bernstein, B. E., Stamatoyannopoulos, J. A., Costello, J. F., Ren, B., Milosavljevic, A., Meissner, A., Kellis, M., Marra, M. A., Beaudet, A. L., Ecker, J. R., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1045 · Cited by 1,892 · cited 1×
“Similar to genomics, an increasing number of evidence suggests that epigenetic modifications, including DNA methylation of CpG islands, post-translational modifications of histones, and nucleosome positioning, are also comprised in the GC initiation, progression, and chemo-resistance [21].”
Background
Cited by
Applications and challenges of biomarker-based predictive models in proactive health management
Zhao, Q., Zhang, C., Zhang, W., Zhang, S., Liu, Q., & Guo, Y. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1633487 · Cited by 80
Beyond Biomarkers: Machine Learning-Driven Multiomics for Personalized Medicine in Gastric Cancer
Ma, D., Fan, C., Sano, T., Kawabata, K., Nishikubo, H., Imanishi, D., Sakuma, T., Maruo, K., Yamamoto, Y., Matsuoka, T., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050166 · Cited by 34
Self-citationMeng, X., Lang, Y., Li, X., Li, Y., Bu, Z., Wu, Y., & Zhang, S. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100639 · Cited by 12
Applications and advances of multi-omics technologies in gastrointestinal tumors
Liu, Y., Gao, F., Cheng, Y., Qi, L., & Yu, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1630788 · Cited by 16
Jin, Q., Chang, Z., Chen, K., Jiang, N., Chen, G., & Lu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690200 · Cited by 9
Metadata
- Authors
- Matsuoka, T., & Yashiro, M.
- Affiliations
- Osaka Metropolitan University (JP)
- Corresponding author
- Yashiro, Masakazu
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-05-28
- Volume
- 25
- Issue
- 11
- Pages
- 5880
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11172243
- OpenAlex
- W4399084028
- Cited by
- 83
- References
- 119
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 3
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- KAKENHI (Grant-in-Aid for Scientific Research) (21H03008)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- gastric cancer, prognostic factors, predictive biomarkers, multi-omics integration, epigenomics, transcriptomics, proteomics, metabolomics, genomics, biomarker discovery, therapeutic efficacy prediction, targeted therapy
- MeSH terms
- Humans, Prognosis, Stomach Neoplasms, Biomarkers, Tumor, Computational Biology, Genomics, Proteomics, Metabolomics, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer. https://app.cochat.ai/papers/10.3390/ijms25115880
- The paper
- Matsuoka, T., & Yashiro, M. (2024). Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115880
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.